Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 1999LS060 Principal Investigator Weisdorf, Daniel
Phase Phase II
Age Group Both Scope Local
Secondary Protocol No. MT1999-14
Title MT1999-14 Unrelated or partially matched allogeneic donor stem cells for lymphoma, myeloma, and chronic lymphocytic leukemia
Objective This phase II trial is studying how well a donor stem cell transplant works in treating patients with previously treated lymphoma, multiple myeloma, or chronic lymphocytic leukemia.
Treatment Patients will receive a preparative regimen consisting of cyclophosphamide, total-body irradiation, and possibly busulfan followed by stem cell transplantation with bone marrow or umbilical cord blood. Treatment with methotrexate and cyclosporine will be administered last to prevent post-transplant graft vs. host disease.
Description Giving chemotherapy, such as cyclophosphamide and busulfan, and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells from bone marrow or umbilical cord blood may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving methotrexate and cyclosporine after transplant may prevent this graft vs. host disease.
Key Eligibility Patient must have confirmed diagnosis of one of the following: Chronic lymphocytic leukemia, advanced non-Hodgkin lymphoma, advanced Hogdkin disease beyond PR2 or multiple myeloma.
Applicable Disease Sites Bone Marrow
Chronic lymphocytic leukemia (CLL)
Hodgkin's Lymphoma
Leukemia
Lymphoid Leukemia
Multiple Myeloma
Non-Hodgkin's Lymphoma
Therapies Involved Blood and Marrow Transplant
Chemotherapy
Total Body Irradiation (TBI)
Drugs Involved BUSULFAN (MYLERAN)
CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
Total Body irradiation (TBI)
Status Open
Participating Institutions Masonic Cancer Center
Detailed Eligibility Patient may be no more than 55 years of age. Must not have available histocompatible matched related donor, must not have an active uncontrolled infection. A signed informed consent and HIPAA authorization are required; assent form is also required if patient is a minor.
Treatment Type Other
Contact Cancer Information Line nurse Phone: 612-624-2620 - 1-888-226-2376
Email: ccinfo@umn.edu